In partnership with
🧠 The Signal Brief: AI Stock Insights & Picks
It’s April 2026, and while the mainstream media is obsessing over the latest Fed rumors, we’re busy tracking the signals that actually move the needle.
This week, we’ve spotted a $1 million "whale" trade from a Congressman who happens to sit on the very committee overseeing AI and Microsoft's government contracts. Coincidence? Maybe. But in this newsletter, we don't believe in coincidences… we believe in data 😤
But first, we want to show you some stocks that the market loves to hate… but that actually have pretty solid fundamentals and even buy signals.
3 Stocks the Internet Hates (That Might Actually Be Buys)
What we were looking for: stocks where social sentiment is in the gutter, but the AI Score still says "Buy." When everyone hates a stock but the numbers are solid, history says that's often an opportunity.
1. Thermo Fisher Scientific (TMO) — Sentiment: 43/100 | AI Score: 62 (Buy)
Why everyone hates it: Thermo Fisher is the backbone of the life sciences industry. Lab equipment, diagnostics, reagents. They beat Q4 earnings ($6.57 EPS vs $6.44 expected) but then guided 2026 below expectations, citing cautious spending in U.S. academic and government sectors while NIH budgets remain in limbo. Insiders Michael Shafer D and Casper Marc N have been selling shares. Sentiment collapsed from 93 in January to 43 today. The stock is down 19% in three months while industry peers like Amgen (94) and Gilead (100) haven’t fallen nearly as much.
What the data sees that the crowd doesn't:
Brand: 75/100. Thermo Fisher's reputation in the industry remains rock-solid.
User growth: 63/100. Customers aren't leaving. Adoption is still healthy.
89% analysts still rate it "Strong Buy." This isn't a broken company.
They just hiked their dividend 10% and announced a strategic collaboration with Nvidia in January.
Sponsored by FinanceBuzz:
Rare Unlimited Cash Back Match Turns Heads
If you have outstanding credit card debt, getting a new 0% intro APR credit card could help ease the pressure while you pay down your balances.
On top of all that, these top credit cards offer up to an insane 5% cash back perk that gets matched after your first year. That's up to 10% back on qualifying purchases!
Click through to see what all the hype is about.
2. Blue Owl Capital (OWL) — Sentiment: 60/100 (was 90 in January) | AI Score: 65 (Buy)
If you've been reading S&I, you already know Blue Owl. The story has gotten rougher since we last covered it.
Why everyone hates it: Blue Owl manages $307 billion in alternative assets, mostly private credit. This quarter, redemption requests surged: 22% of Credit Income investors asked for their money back, and 41% of Technology Income investors tried to leave. They capped withdrawals at 5% to prevent a stampede. Then Moody's cut their outlook to negative. A shareholder lawsuit followed. The stock is down 48% in three months.
What the data sees that the crowd doesn't:
Brand: 88/100. Employment: 88/100. They're not cutting staff, they're still building.
“Despite redemption-driven volatility, OWL’s liquidity remains robust, and outflows are modest relative to NAV, supporting business model resilience” — JR Research
Blue Owl also just raised a $2.9B for a fund in late March. Hard to raise billions if the sky is truly falling!
3. CF Industries (CF) — Sentiment: 59/100 | AI Score: 61 (Buy)
Why everyone hates it: CF Industries is America's largest nitrogen fertilizer producer. The stock actually ripped 46% over three months thanks to the Iran war spiking fertilizer prices (urea surged 26%). But sentiment has done the opposite, dropping from 90 to 59 since January. Why? The ceasefire just tanked the stock 6% as traders priced in normalized Gulf gas exports killing CF's pricing advantage. On top of that, a plant explosion at their Yazoo City, Mississippi facility last November, which doesn’t help anything. Mizuho downgraded the stock.
What the data sees that the crowd doesn't:
Brand: 88/100. Among the strongest in the chemicals sector.
Fundamental: 61/100 and holding steady despite the noise.
Job postings are up 41%. That’s a company expecting growth!
Beat Q4 earnings for the 4th straight quarter. The business is performing.
Morgan Stanley just raised their target to $135, Barclays to $120, RBC to $125 (all in April).
The Takeaway
This is what happens when you combine traditional financials with alternative data like hiring trends, social sentiment, and web traffic. Sometimes the crowd is right. But sometimes the noise drowns out what the numbers are actually saying.
If you want to run this kind of screener yourself, we offer a 7-day free trial with full access to AI scores, sentiment data, insider moves, and more for every stock in the market. It's what we used to find these three names.
Today’s sponsor:
Speak your prompts. Get better outputs.
The best AI outputs come from detailed prompts. But typing long, context-rich prompts is slow - so most people don't bother.
Wispr Flow turns your voice into clean, ready-to-paste text. Speak naturally into ChatGPT, Claude, Cursor, or any AI tool and get polished output without editing. Describe edge cases, explain context, walk through your thinking - all at the speed you talk.
Millions of people use Flow to give AI tools 10x more context in half the time. 89% of messages sent with zero edits.
Works system-wide on Mac, Windows, iPhone, and now Android (free and unlimited on Android during launch).
📈 Top AI Scorer of the Week
This week, our algorithm is zeroing in on a robotics pioneer that’s currently on sale. While the technical charts look a bit bruised, the internal signals tell a story of massive preparation. From a 64% hiring explosion to a workforce that is overwhelmingly bullish, Intuitive Surgical is showing all the signs of a company gearing up for a major expansio (even if the market hasn't fully realized it yet).
Stock spotlight: Intuitive Surgical (ISRG)
Intuitive Surgical, Inc. is a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery. Known for its innovative Da Vinci Surgical Systems, the company has transformed the field of surgery by developing products that enable surgeons to perform complex procedures with minimal invasiveness, which in turn enhances patient outcomes. With a technological edge and a strong market position, Intuitive Surgical remains a cornerstone in the robotics-assisted surgery industry. The company continues to push the innovation envelope, aiming to expand the capabilities and reach of its surgical systems.
The data:
Revenue: $2.87B. That’s a 14.41% increase since last quarter and a 18.76% increase since the previous year.
Net income: $795M. Increased by 12.83% quarter over quarter and up by 15.91% year over year.
EBITDA: $956M. Down by 5.87% quarter over quarter but up 11.17% year over year.
Price momentum: Negative over the past month (-7.36%) and over the past year (-8.81%).
RSI (relative strength index): Neutral at 64.1, but leaning toward overbought
P/E (price-to-earnings ratio): Potentially overvalued at 57.5
Analyst ratings: 76% “buy”
Alternative data from the past few months:
Job listings: ↑ 64% (this is huge; signals potential growth)
Employee outlook: 84% positive
Web traffic: ↓ 70%
The verdict:
AI score: 73 — buy signal.
Current price: $450.36
Price prediction: $519.86 (15.5% upside)
Bottom line: Based on the provided data, Intuitive Surgical demonstrates strong revenue and net income growth, indicating a fundamentally solid company with positive growth trajectory. However, the quarter-over-quarter decline in EBITDA and high P/E ratio suggest the need for a bit of cautious evaluation.
While technical indicators show a bearish trend and short-term price declines, alternative data such as increased job postings and high employee sentiment present a reasonably optimistic outlook. The substantial reduction in website visitors raises concerns about customer acquisition strategies.
Given the mixed signals but predominantly positive fundamental performance and a "buy" indicator from our platform’s AI score, potential investors might consider maintaining a cautiously optimistic outlook on Intuitive Surgical, especially focusing on long-term investment horizons.
Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.
🔎 Alt-Data Signals
What’s cooking in markets right now?
Congress Trades
We only want to talk about one main Congress trade today: Rep. Josh Gottheimer just bought up to $1M in MSFT call options on March 25th.
You read that right!
And he does hold positions on subcommittees that have a lot to do with Microsoft: he’s on the House Intelligence Committee and on the Financial Services subcommittee for Digital Assets, Financial Technology, and Artificial Intelligence.
And Microsoft has multi-billion dollar contracts with the government 👀
Reddit Alerts
(You can get all of these alerts as notifications on your phone with the AltIndex App)
Palantir (PLTR): People are actively discussing Palantir (PLTR) on Reddit, with a focus on its recent performance. Some users are commenting on the stock's significant drop from its all-time high and the substantial gains needed to return to that level. Others are sharing their successful trading strategies related to PLTR, while some express skepticism about the future performance of the stock.
Google (GOOG): People are actively discussing Google's future valuation, with speculative remarks about it reaching 150 trillion in 2027. There is also mention of a potential partnership between Intel (INTC) and Google (GOOGL), indicating some interest in the tech sector collaborations. Lastly, there's a comparison debate involving Google, Microsoft, Meta, and Amazon regarding their innovative capabilities.
Alternative Data Points of Interest from the Past 3 Months:
The Children’s Place’s (PLCE) job postings decreased by 99%.
E. W. Scripps’s (SSP) job posts increased by 34%.
Kroger’s (KR) Facebook engagement is up by 162%.
Want instant access to scores like this—any time, before the news hits?
📉 Lowest Scores: Stocks Losing Signal
These are the five worst-rated stocks on our platform. Our AI model sees these as strong sell signals. Always do your own research.
👆 Need real-time alt-data at scale?
AltIndex powers hedge funds, fintechs, and financial publishers with institutional-grade signal access.
If you need API integrations, full historical datasets, or white-labeled solutions, reach out at [email protected].
🐦 Tweet of the Week
👋 See You Next Week
That’s it for today. Hope you found these signals helpful and/or interesting.
Have a great weekend, and happy trading.
— Brandon and Blake
The information provided in AltIndex is for informational and educational purposes only and should not be construed as financial advice, investment advice, or a recommendation to buy or sell any securities. AltIndex is not a registered investment advisor, broker-dealer, or licensed financial planner. Always do your own research and consult with a licensed financial advisor before making any investment decisions. We may hold positions in or receive compensation from the companies or products mentioned. Disclosures will be made where applicable. Past performance is not indicative of future results. All investing involves risk, including the loss of principal.
Stocks & Income, AltIndex, Finance Wrapped, The Chain, and Future Funders are all owned by Invested, Inc.